Bio Path Holdings Inc (BPTH)

$1.81

-0.02

(-1.09%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $1.80
    $1.84
    $1.81
    downward going graph

    0.55%

    Downside

    Day's Volatility :2.17%

    Upside

    1.63%

    downward going graph
  • $1.59
    $25.67
    $1.81
    downward going graph

    12.15%

    Downside

    52 Weeks Volatility :93.81%

    Upside

    92.95%

    downward going graph

Returns

PeriodBio Path Holdings IncIndex (Russel 2000)
3 Months
-38.01%
0.0%
6 Months
-77.93%
0.0%
1 Year
67.59%
0.0%
3 Years
-73.07%
-19.6%

Highlights

Market Capitalization
3.8M
Book Value
- $3.48
Earnings Per Share (EPS)
-25.26
PEG Ratio
0.0
Wall Street Target Price
20.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-138.36%
Return On Equity TTM
-430.79%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-14.2M
Diluted Eps TTM
-25.26
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-5.53
EPS Estimate Next Year
-3.65
EPS Estimate Current Quarter
-4.54
EPS Estimate Next Quarter
-4.6

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Bio Path Holdings Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1004.97%

Current $1.81
Target $20.00

Technicals Summary

Sell

Neutral

Buy

Bio Path Holdings Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Bio Path Holdings Inc
Bio Path Holdings Inc
-14.96%
-77.93%
67.59%
-73.07%
-87.2%
Moderna, Inc.
Moderna, Inc.
-11.58%
21.5%
-1.52%
-62.55%
762.21%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.03%
12.81%
46.27%
81.23%
258.69%
Novo Nordisk A/s
Novo Nordisk A/s
-7.55%
24.69%
62.32%
198.21%
443.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.5%
11.69%
37.68%
150.78%
182.38%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Bio Path Holdings Inc
Bio Path Holdings Inc
NA
NA
0.0
-5.53
-4.31
-1.38
NA
-3.48
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.53
31.53
1.46
44.41
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.49
45.49
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.66
31.66
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Bio Path Holdings Inc
Bio Path Holdings Inc
Buy
$3.8M
-87.2%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.5B
762.21%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.5B
258.69%
31.53
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$589.9B
443.55%
45.49
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.0B
182.38%
31.66
39.46%

Insights on Bio Path Holdings Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 58.8% return, outperforming this stock by 8.0%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 198.2% return, outperforming this stock by 271.3%

Institutional Holdings

  • Vanguard Group Inc

    0.82%
  • BlackRock Inc

    0.14%
  • Tower Research Capital LLC

    0.12%
  • UBS Group AG

    0.07%

Company Information

bio-path is a publicly traded biotechnology company focused on developing therapeutic products utilizing its proprietary dnabilize™ technology designed to distribute nucleic acid drugs throughout the human body with a simple intravenous infusion. the company’s initial focus is in oncology. bio-path’s lead product candidate, prexigebersen, (bp1001), is in phase ii clinical trials for aml in combination with ldac in elderly de novo patients. the safety segment of the phase ii trial for prexigebersen + dasatinib in blast-phase and accelerated phase cml patients is expected to begin in 2017. bio-path’s second drug candidate, bp1002, is ready for the clinic where it will be evaluated in lymphoma and solid tumors. the technology behind prexigebersen is called dnabilize™ technology. dnabilize is a liposomal antisense dna platform with two critical improvements in oligonucleotide therapeutics. the main benefits to the patient are, 1: we have never had a single patient experience thrombocytopen

Organization
Bio Path Holdings Inc
Employees
10
CEO
Mr. Peter H. Nielsen MBA
Industry
Health Technology

FAQs